# Tackling diabetes with machine learning

Mathieu Ravaut

Work done while working at Layer 6 AI

SUTD April 20th, 2021



## About me

- [FRANCE] M.Eng, Applied Mathematics @ Ecole Centrale Paris (2014 2018)
- [SG] ML Research Intern @ Thales Solutions Asia, @ A-STAR (2016 2017)
- [CANADA] MSc Applied Computing @ University of Toronto (2017 2018)
- [CANADA] ML Research Scientist at Layer 6 AI, Toronto (2018 2020)
  - The AI lab of TD Bank, Canada's second largest bank
  - Projects on ML & NLP for healthcare, insurance, recommendation systems
- [back in SG!] NLP PhD candidate @ NTU (2021 ) w Prof. Shafiq Joty
- ... love machine (& deep) learning <3



Give an idea of how an **applied research** project in machine learning is done **end-to-end** in industry.

Machine (& deep) learning is talked about everywhere these days, but what is it really all about?

What can machine (& deep) learning do, how does it bring value?



Give an idea of how an **applied research** project in machine learning is done **end-to-end** in industry.

Machine (& deep) learning is talked about everywhere these days, but what is it really all about?

What can machine (& deep) learning do, how does it bring value?

In this case, we tackle the following question:

How can machine (& deep) learning be leveraged to make a change against diabetes with the data collected by the public healthcare system (specifically, in Ontario, Canada)?



Give an idea of how an **applied research** project in machine learning is done **end-to-end** in industry.

Machine (& deep) learning is talked about everywhere these days, but what is it really all about?

What can machine (& deep) learning do, how does it bring value?

#### Challenges:

- Patient-level health data is anonymized and access is (very) restricted.
- Data is **not clean**: missing values, non-consistent codes, etc
- Data is not prepared for machine (& specifically deep) learning.



#### Outcomes:

- Type-2 Diabetes Onset Prediction at the Population-Level using Machine Learning and Routinely Collected Administrative Health Data, Ravaut et al. (Jama Network Open, 2021)
- Predicting Adverse Outcomes due to Diabetes Complications with Machine Learning Using Administrative Health Data, Ravaut et al. (Nature NPJ Digital Medicine, 2021)



## Outline



- B. Task.
- C. Data.
- D. Framework.
- E. Model.
- F. Results.
- G. Example.

- Diabetes is the one of the most prevalent chronic diseases in the world with ~8.8% prevalence rate (10% in Ontario, 10.5% in Singapore)
- **Dramatic complications** severely impairing one's life:
  - Amputation
  - Blindness
  - Kidney failure
  - 0 ...
- That makes diabetes the costliest chronic disease for Ontario.
- If spotted early enough, these complications can be **avoided**.
  - Better patient outcome
  - Save costs for the Ontario province.



Quick estimation of the total yearly cost of diabetes complications hospitalizations:

Complication	Cases per year in Ontario (approx)	Average cost per hospitalization (\$CAD))	Total cost (M \$CAD))
Hyper/hypo - glycemia	6,790	10,534	71
Tissue infection	36,063	21,868	789
Retinopathy	2,563	13,333	34
Cardiovascular	64,354	17,863	1,150
Amputation	19,976	9,568	191

Total: ~2.24B \$CAD /year! layer6

- Machine learning is said to enable personalized medicine.
- But where/how can machine learning be applied to diabetes?



- Machine learning is said to enable personalized medicine.
- But where/how can machine learning be applied to diabetes?
- Use cases
  - <u>Diabetes onset prediction</u>
     Predict whether the patient is going to get diabetes (binary class.)
  - <u>Diabetes complications prediction</u>
     Predict whether the patient is going to get a set of complications (several binary class.)

- There are already existing data science studies on diabetes.
- What is specific here?
  - Go beyond models focusing on a small subgroup and include the full population.
     Very little exclusions.
  - Very large scale: millions of patients, across more than 10 years.
     A recent study published in Nature had 900 patients.
  - Deploy the diabetes onset and the diabetes complications systems in Ontario.

### B. Task

- Diabetes onset prediction: **binary** classification
- Diabetes complications: **multi-label** binary classification We identify **severe outcomes** of diabetic complications:
  - Hospitalizations
  - Ambulatory usage



## B. Task

#### But what are the labels?

- Unlike on Kaggle, labels were not given.
  - We had to build them ourselves.
- We flag ICD-10 codes:
  - Representing diabetes: find the earliest one
  - Corresponding to hospitalizations due to a diabetes complication
- Inherent noise:
  - Choice of codes
  - Reporting error in the database
  - Billing bias
  - A code is not the complication itself



## B. Task

- We predict the incidence of diabetes/complications at each quarter.
- We pick **5 complications**:
  - Severe hyper or hypoglycemia
  - Tissue infection
  - Retinopathy
  - Cardiovascular event (stroke, heart failure)
  - Amputation





## B. Task - statistics

Disease	Quarterly incidence (%)	
Diabetes	0.21	
1 - Hyper/hypo - glycemia	0.14	
2 - Tissue infection	0.65	
3 - Retinopathy	0.04	
4 - Cardiovascular	1.09	
5 - Amputation	0.35	

Note the **extreme sparsity** of some complications...



### C. Data - cohort

- Need to use 2 different cohorts (one for each task)
- To predict diabetes:
  - Purely random sample of 3m people
  - Negative examples are patients not developing diabetes in the future
- To predict diabetes complications
  - Everyone developing diabetes at some point: ~2m
     Goal is to include as many people as possible.
- **Exclusions** if one of the following is broken:
  - Alive as of January 1st, 2012
  - Date of Last Contact (DOLC) after the target window
  - Landing Date in Canada before the end of the observation



### C. Data - source

- Our data partner, ICES, has around **100 unique datasets**.
  - The first phase is to **pick** the relevant ones for our study.
- Some datasets are **extremely large**:
  - $\circ$  > 2B rows
  - > 50GB
  - Does not fit in the RAM!
    - We read the dataset by chunks of 2m rows.
- Files are in SAS (not cool for ML).

### C. Data - datasets

- **Stationary** data (3 datasets)
- **Geographical** data (yearly) (4 datasets)
- **Chronic** diseases (yearly binary flags) (6 datasets)
- **Observations** (heterogenous times) (5 datasets)
- **Lab** values (1 dataset)
- The split is based on the temporality of the data.

**19 datasets** in total



### C. Data - features

#### Features include:

- Year of birth
- Gender
- Latitude, longitude of the patient's address
- Flag for asthma
- Physician specialty
- Diagnosis code linked to a hospitalization
- Quantity of drugs bought at a given time
- A1C measurement (important for diabetes)
- Cholesterol measurement

...

### C. Data - features

#### Features include:

- Year of birth
- Gender

Typical demographic data

Latitude, longitude of the patient's address

neighborhood information

Flag for asthma


Built-in flags for chronic diseases

- Physician specialty
- Diagnosis code linked to a hospitalization
- Quantity of drugs bought at a given time
- A1C measurement (important for diabetes)
- Cholesterol measurement

Diverse observations (codes, lab values, etc)

..


### D. Framework




General way to approach time series problems...



## D. Framework




 Multiple, varying numbers of observations from each dataset in a patient's recent history:



- We also have stationary patient information: birth year, etc.
- How to summarize data into a fixed-length vector?

Let's say we have multiple observations from the same dataset in a given time window:



Time bin contains 3 observations from dataset A.


**Dummy variable** (1-hot or k-hot)

**Averaging** values gives us a **unique vector**.

Averaging is just one way to aggregate...



There are several ways to define **aggregation periods**. For instance when looking at 2 years of patient's history:



Averaging is not the only way to aggregate temporal data:

- Standard deviation
- Minimum, maximum
- Amplitude (max min)
  - Needs at least two observations
- Trend (last first)
  - Needs at least two observations
- ..

Some **manually-engineered features** turn out to be very important:

- Age
- Age when arriving in Canada
- **Time since** last observation from a given dataset.
- Time since last measurement of given lab.
- Mean/std of time between consecutive observations
- Count and cumulative count of observations.
- Complications history.
- ..

#### Be creative!




## D. Framework

- Our model includes several stationary features:
   Birth year, country of birth, etc
- We concatenate the array of stationary features to the arrays of temporal ones.
- We extract A LOT of features, then keep the ones with the highest absolute feature contribution => typically top 500/700
- No feature hand-picking.



## D. Framework - split

We use a training/validation/test split in terms of **patients and time**:



## Takeaways on data + framework

- The way you prepare the data is really super important.
   Spend time on it!
- <u>Feature engineering</u>:
   Think about which features you could create that could be relevant for the problem you are tackling.
- Split:
   Use a clean train/val/test split.
   In almost all cases, you must split on patients.
   For temporal data, it is also best to split on time.

### E. Model

The model can be any machine learning model suitable for binary classification:

- Logistic regression
- Decision tree or random forest
- Gradient boosting:
   Xgboost, lightgbm, etc
- Neural networks:
   MLP, LSTM, GRU, Transformer, ODE-GRU, etc



# E. Model: deep learning vs gradient boosting

A long-running competition between both approaches!

#### Deep learning:

- +++ Pros:
  - SOTA for CV, NLP, Speech
  - No feature engineering!
  - Can handle temporal data nicely (RNNs, Transformers)
- --- Cons:
  - Tricky to optimize
  - Need to preprocess and normalize input features
  - Newer SOTA models (e.g., Transformer-based) are large, GPU-demanding and slow to train
    - "Black-box"

#### Gradient boosting:

- +++ Pros:
  - SOTA for tabular data
  - No need to normalize input features
  - More robust to noisy features
  - Easier interpretability
- --- Cons:
  - Need feature engineering to reach best performance
  - Not designed for temporal data



# E. Model: deep learning vs gradient boosting

A long-running competition between both approaches!

#### Most real-life data

#### Deep learning:

- +++ Pros:
  - SOTA for CV, NLP, Speech
  - No feature engineering!
  - Can handle temporal data nicely (RNNs, Transformers)
- --- Cons:
  - Tricky to optimize
  - Need to preprocess and normalize input features
  - Newer SOTA models (e.g., Transformer-based) are large, GPU-demanding and slow to train
  - "Black-box"


#### Gradient boosting:

- +++ Pros:
  - SOTA for tabular data
  - No need to normalize input features
  - More robust to noisy features
  - Easier interpretability
- --- Cons:
  - Need feature engineering to reach best performance
  - Not designed for temporal data



## E. Model: LSTMs

- "Long Short-Term Memory" (Hochreiter and Schmidhuber, 1997) are a variant of RNN great at modeling long-term dependency
- Brought breakthrough performance on speech (2013), then NLP (2014)




Source: http://colah.github.io/posts/2015-08-Understanding-LSTMs/



## E. Model: TabNet

- "Attentive interpretable tabular learning" (Google, 2019)
- Neural network designed for tabular data.
- Leverages a lot the attention mechanism.
- Attentive transformer decides which bits of the input features (x) it needs to pay attention (mask) at each step



Source: https://sachinruk.github.io/blog/tensorflow/2021/04/05/Tabnet\_From\_Scratch.html



#### E. Model

The model can be any machine learning model suitable for binary classification:

- Logistic regression
- Decision tree or random forest
- Gradient boosting: Xgboost, Hghtgbm, etc

Xgboost is our favorite, because:

- Higher AUC
- Interpretable

Neural networks:


MLP, LSTM, GRU, Transformer, ODE-GRU, etc



#### E. Model: xgboost

https://xgboost.readthedocs.io/en/latest/

- "Xgboost: a scalable boosting tree system" (Tianqi Chen, 2016)
- The unsung hero of machine learning
- Gradient Boosting Machine with Decision Trees as Base Learners
- Use second-order Taylor expansion for gradient boosting, i.e. gradients scaled by the hessians
- Include many different regularization techniques



#### E. Model: xgboost

#### Most important parameters to tune:

- max\_depth
   Complexity of the base tree.
- eta
   Learning rate.
- min\_child\_weight
   Minimum number of instances that have to end up in each leaf.
   Increase it to fight overfitting.
- subsample
   Take a sample of rows.
- colsample\_bytree, colsample\_bylevel, colsample\_bynode
   Take a sample of columns.



#### E. Model

Thoughts on choosing a model:

- A higher capacity, fancier model (ex: very deep net) is not always the best choice.
- Consider other criteria than performance:
  - Size and GPU need
  - Speed of training
  - Interpretability extremely important in healthcare!
  - Processing requirements (ex: normalizing features)
- Overall, the model is less important (and less time consuming) than the data prep!

#### E. Model

Thoughts on choosing a model:

- A higher capacity, fancier model (ex: very deep net) is not always the best choice.
- Consider other criteria than performance:
  - Size and GPU need
  - Speed of training
  - Interpretability extremely important in healthcare!
  - Processing requirements (ex: normalizing features)
- Overall, the model is less important (and less time consuming) than the data prep!





### Takeaways on the model

- Start with a **very simple model**: LR, small xgboost
  - Simple means fast to train.
  - o Is the performance what you expected?
  - If it's too high: is there a leakage?
  - If it's **too low**: is there a **bug** in your data preparation?
  - Iterate
- Tuning parameters is less important than tuning how you prepared the data.
- Try models of **various nature**: gradient boosting, deep learning, etc.
- Don't assume that one model will be better than all others.

  Deep learning is only awesome on images, text or speech!



#### F. Results

- Accuracy is the most naive way to measure classification performance.
- For unbalanced tasks such as this one, the Area Under the ROC Curve (AUC) is better suited.
- There are many other metrics:
  - Precision
  - Recall
  - o Lift
  - O ...
- And other things to measure aside from performance!



### F. Results - feature importance

- We can get the feature importance for an xgboost model with the Shapley values.
- Shapley values come from the game theory literature.
   "A Value for n-person Games" (Shapley, Lloyd S., 1953)
- Shapley values are the only feature importance method satisfying a set of important properties:
  - Efficiency
  - Symmetry
  - Dummy
  - Additivity





#### F. Results - calibration

- Why bother with calibration?
   Our model outputs probabilities ... but do these probabilities match with the actual probabilities of getting the complication?
- Think about **deployment**, and a doctor reading these numbers.
- Calibration curves are simply the curves of (predicted\_prob, real\_prob) for bins of patients.
- We typically cut the population into 100 bins of patients and compute the mean probabilities (predicted and real) for each bin.




## F. Results - diabetes onset (5 years ahead)







# F. Results - diabetes onset (5 years ahead)




Bin	Age	Females (%)	Immigrants (%)	Time in Canada (years)	Ethnicity marginalization score	Deprivation marginalization score	HbA1c
Model prediction							
Top 1%	58.3	59.6	38.8	17.3	4.22	3.63	5.84
Next 5%	59.4	42.3	26.5	18.4	3.85	3.45	5.81
Next 15%	58.3	40.8	16.5	19.4	3.44	3.15	5.73
Bottom 79%	31.8	55.3	11.4	19.7	3.38	2.87	5.53
Label							
Positive	53.7	49.2	19.5	19.1	3.54	3.15	5.92
Negative	37.4	52.5	13.2	19.6	3.42	2.95	5.63


<sup>(</sup>b) Model Prediction Risk Levels



## F. Results - diabetes complications (3 years)



## F. Results - diabetes complications (3 years)



#### Takeaways on the results

There are **many ways** to evaluate the performance of a machine learning model applied to a healthcare problem:

- Classification performance: AUC, (accuracy)
- Feature importance with the Shapley values
- Calibration curves
- Precision/recall/lift at different thresholds.
- ...

Ideally, if you have the time, try them all!

Let's apply our model to screen for tissue infection.

Let's look at Eddie (fake data and name) at the end of 2010 and at his outcome in the

Feature

Feature

last quarter of 2015:

	portance:	value:
Birth year	-0.089	1975
History of blood transfusion	-0.05	0
Quant. of medication bought in last 2 years	-0.045	0
Is the patient male?	-0.043	1
Average A1C in last 2 years	-0.04	6.1
History of diabetic complication	-0.037	0
Long-term care in the last 2 years	-0.034	0

Let's apply our model to screen for tissue infection.

Let's look at Eddie (fake data and name) at the end of 2010 and at his outcome in the

Feature

Feature

last quarter of 2015:

Feature name: im	portance:	value:
Birth year	-0.089	1975
History of blood transfusion	-0.05	0
Quant. of medication bought in last 2 years	-0.045	0
Is the patient male?	-0.043	1
Average A1C in last 2 years	-0.04	6.1
History of diabetic complication	-0.037	0
Long-term care in the last 2 years	-0.034	0

Eddie has no history of any diabetic complication.

Let's apply our model to screen for tissue infection.

Let's look at Eddie (fake data and name) at the end of 2010 and at his outcome in the

Feature

Feature

last quarter of 2015:

Feature name:	importance:	value:
Birth year	-0.089	1975
History of blood transfusion	-0.05	0
Quant. of medication bought in last 2 years	s -0.045	0
Is the patient male?	-0.043	1
Average A1C in last 2 years	-0.04	6.1
History of diabetic complication	-0.037	0
Long-term care in the last 2 years	-0.034	0

Which makes sense given that Eddie is young.

Let's apply our model to screen for **tissue infection**.

Let's look at Eddie (fake data and name) at the end of 2010 and at his outcome in the

Feature

Feature

last quarter of 2015:

	ortance:	value:
Birth year	-0.089	1975
History of blood transfusion	-0.05	0
Quant. of medication bought in last 2 years	-0.045	0
Is the patient male?	-0.043	1
Average A1C in last 2 years	-0.04	6.1
History of diabetic complication	-0.037	0
Long-term care in the last 2 years	-0.034	0

Eddie is male.



Let's apply our model to screen for **tissue infection**.

Let's look at Eddie (fake data and name) at the end of 2010 and at his outcome in the

**Feature** 

Feature

last quarter of 2015:

Feature name: im	portance:	value:	_
Birth year	-0.089	1975	
History of blood transfusion	-0.05	0	
Quant. of medication bought in last 2 years	-0.045	0	
Is the patient male?	-0.043	1	
Average A1C in last 2 years	-0.04	6.1	
History of diabetic complication	-0.037	0	
Long-term care in the last 2 years	-0.034	0	

He has no health antecedents in the last 2 years.

Let's apply our model to screen for tissue infection.

Let's look at Eddie (fake data and name) at the end of 2010 and at his outcome in the

**Feature** 

Feature


last quarter of 2015:

Feature name: ir	nportance:	value:
Birth year	-0.089	1975
History of blood transfusion	-0.05	0
Quant. of medication bought in last 2 years	-0.045	0
Is the patient male?	-0.043	1
Average A1C in last 2 years	-0.04	6.1
History of diabetic complication	-0.037	0
Long-term care in the last 2 years	-0.034	0

His A1C is a bit high but still in normal range.

Given this picture of Eddie, our model predicts a **low relative value**:

Birth year	1975
History of blood transfusion	0
Quant. of medication bought in last 2 years	0
Is the patient male?	1
Average A1C in last 2 years	6.1
History of diabetic complication	0
Long-term care in the last 2 years	0



Now let's look at another patient, Alex (**fake data and name**). We look at Alex's history from mid-2008 to mid-2010, and at what happened to this patient in the **3rd quarter of 2015**:

**Footuro** 

Fastura

	ortance:	value:
History of tissue infect. in ambulatory usage	0.307	4
History of diabetic complication	0.238	15
Std of time between ambulatory usage	0.091	54
Tissue infect. in ambulatory usage in last q.	0.065	3
History of tissue infect. in hospitalization	0.065	5
Diagnostic of abscess in last 2 years	0.056	1
Birth year	0.053	1952



Now let's look at another patient, Alex (**fake data and name**). We look at Alex's history from mid-2008 to mid-2010, and at what happened to this patient in the **3rd quarter of 2015**:

Feature

Feature

Feature name: 1mp	ortance:	value:
History of tissue infect. in ambulatory usage	0.307	4
History of diabetic complication	0.238	15
Std of time between ambulatory usage	0.091	54
Tissue infect. in ambulatory usage in last q.	0.065	3
History of tissue infect. in hospitalization	0.065	5
Diagnostic of abscess in last 2 years	0.056	1
Birth year	0.053	1952

Alex is older than Chris

Now let's look at another patient, Alex (**fake data and name**). We look at Alex's history from mid-2008 to mid-2010, and at what happened to this patient in the **3rd quarter of 2015**:

Feature

Feature

Feature name: imp	ortance:	value:
History of tissue infect. in ambulatory usage	0.307	4
History of diabetic complication	0.238	15
Std of time between ambulatory usage	0.091	54
Tissue infect. in ambulatory usage in last q.	0.065	3
History of tissue infect. in hospitalization	0.065	5
Diagnostic of abscess in last 2 years	0.056	1
Birth year	0.053	1952

Alex has a considerable history of diabetic complications...

Now let's look at another patient, Alex (**fake data and name**). We look at Alex's history from mid-2008 to mid-2010, and at what happened to this patient in the **3rd quarter of 2015**:

Feature

Feature

Feature name:	importance:	value:
History of tissue infect. in ambulatory usa	age 0.307	4
History of diabetic complication	0.238	15
Std of time between ambulatory usage	0.091	54
Tissue infect. in ambulatory usage in last	q. 0.065	3
History of tissue infect. in hospitalization	0.065	5
Diagnostic of abscess in last 2 years	0.056	1
Birth year	0.053	1952

... including hospitalizations and ambulatory usage for tissue infection

Now let's look at another patient, Alex (**fake data and name**). We look at Alex's history from mid-2008 to mid-2010, and at what happened to this patient in the **3rd quarter of 2015**:

Feature

Feature

Feature name: imp	ortance:	value:
History of tissue infect. in ambulatory usage	0.307	4
History of diabetic complication	0.238	15
Std of time between ambulatory usage	0.091	54
Tissue infect. in ambulatory usage in last q.	0.065	3
History of tissue infect. in hospitalization	0.065	5
Diagnostic of abscess in last 2 years	0.056	1
Birth year	0.053	1952

..including in the last 3 months!

Now let's look at another patient, Alex (**fake data and name**). We look at Alex's history from mid-2008 to mid-2010, and at what happened to this patient in the **3rd quarter of 2015**:

Feature

Feature

Feature name: imp	ortance:	value:
History of tissue infect. in ambulatory usage	0.307	4
History of diabetic complication	0.238	15
Std of time between ambulatory usage	0.091	54
Tissue infect. in ambulatory usage in last q.	0.065	3
History of tissue infect. in hospitalization	0.065	5
Diagnostic of abscess in last 2 years	0.056	1
Birth year	0.053	1952

Alex has been using the ambulance..

Now let's look at another patient, Alex (**fake data and name**). We look at Alex's history from mid-2008 to mid-2010, and at what happened to this patient in the **3rd quarter of 2015**:

Feature


Feature

Feature name: imp	ortance:	value:
History of tissue infect. in ambulatory usage	0.307	4
History of diabetic complication	0.238	15
Std of time between ambulatory usage	0.091	54
Tissue infect. in ambulatory usage in last q.	0.065	3
History of tissue infect. in hospitalization	0.065	5
Diagnostic of abscess in last 2 years	0.056	1
Birth year	0.053	1952

And has already been diagnosed with an abscess recently.

Given that higher age, and strong history of complications and tissue infection, our model outputs a **high risk score** to this patient:

History of tissue infect. in ambulatory usage	4
History of diabetic complication	15
Std of time between ambulatory usage	54
Tissue infect. in ambulatory usage in last q.	3
History of tissue infect. in hospitalization	5
Diagnostic of abscess in last 2 years	1
Birth year	1959





Thank you!

Questions?

Similar applications of ML for health PhD life vs industry life